High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 25, Issue 11, p.1396-402 (2007)


Aged, Antibodies, Monoclonal, Antigens, CD20, Antineoplastic Agents, Chi-Square Distribution, Combined Modality Therapy, DISEASE PROGRESSION, Female, hematopoietic stem cell transplantation, Humans, Iodine Radioisotopes, Lymphoma, B-Cell, Male, Middle Aged, Radioimmunotherapy, Radiotherapy Dosage, Survival Analysis, Treatment Outcome


The majority of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) are older than 60 years, yet they are often denied potentially curative high-dose therapy and autologous stem-cell transplantations (ASCT) because of the risk of excessive treatment-related morbidity and mortality. Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy.